You are now leaving this website.
Are you sure?
NO
YES
  1. CORPORATE - 07-11-2016

    Kedrion Biopharma and Kamada Announce FDA Acceptance of BLA Submission for Human Rabies Immunoglobulin as a Post-Exposure Treatment

    FDA has accepted for review a BLA for a human anti-rabies immunoglobulin (IgG) therapy

    read more 
  2. CORPORATE - 13-09-2016

    Kedrion Biopharma set for strong presence at 2016 IgNS Meeting

    Kedrion Biopharma will be a bronze sponsor at the Immunoglobulin National Society (IgNS) 2016 5th National Conference

    read more 
  3. CORPORATE - 01-09-2016

    Kamada and Kedrion Seek FDA Approval of Human Rabies Immunoglobulin

    Kamada and Kedrion, collaborators on development and commercialization of post-exposure treatment for suspected rabies, announced today the filing of a BLA with the FDA.

    read more 
  4. CORPORATE - 22-08-2016

    Kedrion Biopharma to attend 14th International Symposium of GBS/CIPD Foundation

    Kedrion Biopharma will be a Silver Sponsor at the 14th International Symposium of GBS/CIPD Foundation

    read more 

Pages

For more information please contact: [email protected]